Obesity trials are shaking things up with the GLP-1/GLP-2 combo. But let’s not get too excited just yet. While these trials have shown some promise, the reality is a bit more complicated.
For instance, the CagriSema REDEFINE 4 trial reported a whopping 23% weight loss after 84 weeks, but it didn’t beat tirzepatide in head-to-head comparisons. Ouch.
And what’s the deal with Pfizer’s PF-3944? Sure, it boasts up to 12.3% placebo-adjusted weight loss after just 28 weeks. But who wants to be a guinea pig for a drug that might just play games with your appetite and energy levels? People expect results, not a rollercoaster of hunger pangs and energy slumps. Phase 2b studies have shown continued efficacy without a plateau in weight loss at 28 weeks, indicating potential for further improvements. Notably, CagriSema’s 84-week duration highlights the need for long-term data to assess its true effectiveness.
The GLP-1 receptor agonists, like liraglutide, have shown some decent results. T2D patients lost 4% of their weight in 56 weeks, and non-diabetics? They managed 5.4%. That’s not exactly breaking records.
Sure, these drugs can lower inflammation and improve lipids, but they don’t fix everything. Some T2D folks still face adipose tissue dysfunction. Talk about a mixed bag.
These drugs can reduce inflammation and enhance lipids, but they don’t address all issues—some T2D patients still struggle with adipose tissue dysfunction.
Then there’s the UBT251 trial, which claimed up to 19.7% weight loss in a Chinese cohort. But let’s be real: gastrointestinal side effects, even if they’re mild, are still side effects. No one wants a drug that doubles as a stomach ache.
In the grand scheme of things, GLP-1/GLP-2 combos may be safe, but they’re not miracle workers. With Pfizer planning over 20 trials by 2026, it seems they’re throwing everything at the wall to see what sticks.
Meanwhile, the long-term results are still to come, leaving many to wonder if this is just another fad in the ever-evolving world of obesity treatments.
